Quick Answer
Acumen Pharmaceuticals, Inc. reported R&D Expense of $104.89 million for fiscal year 2025.
Acumen Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $104.89M | +11.8% |
| 2024 | $93.80M | +121.7% |
| 2023 | $42.32M | +30.8% |
| 2022 | $32.36M | +163.0% |
| 2021 | $12.30M | +53.9% |
| 2020 | $8.00M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $21.97M | -19.4% | -40.8% |
| June 30, 2025 | $37.12M | +90.1% | +46.9% |
| March 31, 2025 | $25.27M | +103.0% | -7.3% |
| September 30, 2024 | $27.25M | +143.7% | +39.5% |
| June 30, 2024 | $19.53M | +113.9% | +56.9% |
| March 31, 2024 | $12.45M | +42.9% | +11.4% |
| September 30, 2023 | $11.18M | +34.5% | +22.4% |
| June 30, 2023 | $9.13M | +24.8% | +4.8% |
- Acumen Pharmaceuticals, Inc. showed an increase of +11.8% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Acumen Pharmaceuticals, Inc.’s r&d expense has grown by 1211.6% (from $8.00 million to $104.89 million).
- The most recent figure is from Acumen Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: